New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:08 EDTPSDV, ALIMpSivida announces resubmission of NDA for ILUVIEN
pSivida Corp. (PSDV) announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration. In the resubmission, pSividas licensee, Alimera Sciences (ALIM), responded to questions raised in the FDAs October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe. Alimera is awaiting the FDAs acceptance of the resubmission and a Prescription Drug User Fee Act date. pSivida will report that information when it becomes available.
News For PSDV;ALIM From The Last 14 Days
Check below for free stories on PSDV;ALIM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:20 EDTPSDVpSivida receives marketing authorization in Denmark for ILUVIEN
Subscribe for More Information
16:13 EDTALIMAlimera receives marketing authorization in Denmark for treatment of DME
Subscribe for More Information
July 28, 2014
16:26 EDTPSDVpSivida says ILUVIEN receives marketing approval in Norway
Subscribe for More Information
16:04 EDTALIMAlimera Sciences says NMEB grants marketing authorization to ILUVIEN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use